Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET
Company Participants
Marek Ciszewski - Senior Vice President, Investor Relations
Denny Lanfear - Chief Executive Officer
Theresa Lavallee - Chief Development Officer
Rosh Dias - Chief Medical Officer
Paul Reider - Chief Commercial Officer
McDavid Stilwell - Chief Financial Officer
Conference Call Participants
Salim Syed - Mizuho
Douglas Tsao - HC Wainwright
Georgi Yordanov - Cowen
Steve Boland - Bank of America
Chris Schott - JPMorgan
Ash Verma - UBS
Operator
Good day and thank you for standing by. Welcome to the Coherus Biosciences Inc. Q3 2022 Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Marek Ciszewski, Senior Vice President of Investor Relations. Marek, please go ahead.
Marek Ciszewski
Thank you, Rael. Good afternoon, everyone and thank you for joining us. We issued a press release earlier today announcing our financial results for the third quarter of 2022. This release can be found on the Coherus Biosciences website and is also attached to our Form 8-K.
Today’s call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, our ability to gain approval for multiple new products and launch them, timing of the end of our decline in revenue and timing of our ability to gain market share for any of our approved products, expectations about revenue growth, projections of expenses and revenue, our future manufacturing capacity and our ability to return to profitability in 2024.
All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we should say as well as the documents that we file with the SEC, including those in our quarterly report on Form 10-Q for the third quarter that we filed today. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statements. Quarterly results for the third quarter are not necessarily indicative of results for future periods.
With me today on today’s call are Denny Lanfear, CEO of Coherus, Dr. Theresa Lavallee, Chief Development Officer; Dr. Rosh Dias, Chief Medical Officer; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, Chief Financial Officer.